Research Article

Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients

Jinpeng Zhuang, Jianing Zu, Changlong Zhou, Yi Sun, Pengyu Kong, and Yongbin Jing

Department of Orthopaedic Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin 150081, China

Correspondence should be addressed to Yongbin Jing; jingyongbin@hrbmu.edu.cn

Received 11 July 2022; Accepted 30 August 2022; Published 14 September 2022

Academic Editor: Aneesha Acharya

Copyright © 2022 Jinpeng Zhuang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) leads to significant morbidity. Other coadministered drugs may modulate the risk for BRONJ. The present study aimed to leverage bioinformatic data mining to identify drugs that potentially modulate the risk of BRONJ in cancer.

Methods. A GEO gene expression dataset of peripheral blood mononuclear cells related to BRONJ in multiple myeloma patients was downloaded, and differentially expressed genes (DEGs) in patients with BRONJ versus those without BRONJ were identified. A protein-protein interaction network of the DEGs was constructed using experimentally validated interactions in the STRING database. Overrepresented Gene Ontology (GO) molecular function terms and KEGG pathways in the network were analysed. Network topology was determined, and 'hub genes' with degree ≥ 2 in the network were identified. Known drug targets of the hub genes were mined from the 'drug gene interaction database' (DGIdb) and labelled as candidate drugs affecting the risk of BRONJ.

Results. 751 annotated DEGs (log FC ≥ 1, p < 0.05) were obtained from the microarray gene expression dataset GSE7116. A PPI network with 633 nodes and 168 edges was constructed. Data mining for drugs interacting with 49 gene nodes was performed. 37 drug interactions were found for 9 of the hub genes including TBP, TAF1, PPP2CA, PRPF31, CASP8, UQCRB, ACTR2, CFLAR, and FAS. Interactions were found for several established and novel anticancer chemotherapeutic, kinase inhibitor, caspase inhibitor, antiangiogenic, and immunomodulatory agents. Aspirin, metformin, atrovastatin, thrombin, androgen and antiandrogen drugs, progesterone, Vitamin D, and Ginsengoside 20(S)-Protopanaxadiol were also documented.

Conclusions. A bioinformatic data mining strategy identified several anticancer, immunomodulator, and other candidate drugs that may affect the risk of BRONJ in cancer patients.

1. Introduction

Bisphosphonates are antiresorptive drugs, analogous to pyrophosphates and potently inhibit osteoclast-mediated bone resorption [1]. They are commonly applied in bone cancers, management of bone metastasis, hypercalcemia of malignancy or chronic kidney diseases, osteoporosis, and bone diseases such as Paget’s disease [2–5]. Among these, cancers comprise a chief indication for high dose and intravenous bisphosphonate therapy [2, 6]. Presently, three generations of bisphosphonate drugs have been developed with increasingly greater potency [7]. The numbers of patients with cancer-associated bone metastasis under bisphosphonate therapy are rapidly increasing globally [8–10].

Bisphosphonate related osteonecrosis of the jaw (BRONJ) is an important complication of bisphosphonate therapy, resulting in exposed and necrotic bone tissue in the jawbone without spontaneous healing for greater than 8 weeks [11, 12]. Highly potent intravenous bisphosphonates used in cancer are more commonly implicated in BRONJ as compared to oral bisphosphonates [13–15]. Local risk factors including trauma, periodontal disease, and dental procedures such as extractions or implant placements are frequently implicated as risk factors of BRONJ, while
spontaneous occurrence; especially in patients on long term bisphosphonates is also noted [13–16]. The biological mechanisms of BRONJ are not completely understood at the molecular level although multiple mechanisms have been summarized. These include osteoclast apoptosis and impaired bone turnover, inhibition of angiogenesis and epithelial cell inhibition, which, particularly in patients with reduced immune function such as in cancer, can inhibit bone repair mechanisms and result in necrosis in response to trauma or infection [17]. A number of nonlocal risk factors for BRONJ have been identified. These include older age, presence of cancer and its type, type of bisphosphonate agent and duration of therapy, concomitant osteoporosis or osteopenia with cancer, diabetes, corticosteroid therapy, alcohol and chemotherapeutic agents, and gene polymorphisms including MMP2 and CYP2C8 [17, 18].

Medication related osteonecrosis of the jaws (MRONJ) in cancer patients has been associated with multiple predictors including chemotherapy, cancer type (breast, prostate cancer and multiple myeloma), bisphosphonate zolendronic acid, denosumab, and novel anticancer agents, reflecting a complex and cumulative risk structure [19]. Coadministration of anticancer drug cyclophosphamide with bisphosphonate zolendronic acid was found to induce BRONJ in a dose-dependent manner with increase in the dose of cyclophosphamide [20]. A number of drugs including cytotoxic chemotherapeutic agents, targeted therapies including tyrosine kinase inhibitors, angiogenesis inhibitors, mTOR inhibitors, and immunotherapy agents have been associated with MRONJ, independent of bisphosphonates [21]. It follows that drugs coadministered with bisphosphonate agents may potentially affect the risk for BRONJ. As cancer patients are particularly likely to receive multiple pharmacological agents; an understanding of drugs affecting BRONJ risk is warranted. The complex nature of the pathogenesis of this condition underscores the need to understand drug-drug interactions in context of BRONJ/MRONJ with particular relevance to discovery of agents that may exacerbate risk and those that may serve as protective factors.

Presently the amount of clinical or experimental evidence in this regard is very limited. Bioinformatics analyses of gene expression datasets related to BRONJ and MRONJ have identified several candidate biological mechanisms [22, 23]. However, bioinformatics data mining for other drugs possibly implicated in BRONJ has not been reported. Therefore, the present study aimed to perform bioinformatics-based identification of candidate drug agents that might affect the risk of BRONJ in cancer patients. These data can provide a theoretical basis for the identification of potential agents that, when administered with bisphosphonates might increase or decrease the risk of BRONJ, and thus direct experimental research.

2. Methods

2.1. Dataset and Identification of DEGs. A microarray gene expression dataset GSE7116 [24] was downloaded from the Gene Expression Omnibus (GEO). The dataset contained peripheral blood mononuclear cell samples from 11 patients with multiple myeloma and BRONJ and 10 multiple myeloma patients on bisphosphonate therapy without the occurrence of BRONJ. Differential gene expression (DEG) analysis was performed using the GEO2R tool, at a threshold of Benjamini & Hochberg (False discovery rate) corrected FDR p value<0.05 and Log fold change (Log FC) >1.5, with limma precision weights applied.

2.2. Protein-Protein Interaction (PPI) Network and Functional Enrichment Analysis. The DEGs list was imported into STRING v. 11.5 [25] for the construction of a PPI network. The parameters for network construction were; experimental data as active interaction sources, full STRING network type, and a minimum required interaction score of 0.9 (highest confidence). These parameters and thresholds were selected to identify the genes with the highest evidence support. Disconnected nodes were hidden in the PPI network visualization. Network topology was analysed. In addition, k-means clustering was applied to group the gene-nodes into 3 clusters. Functional enrichment analysis for the network was performed for identifying overrepresented Gene Ontology (GO) molecular functions and KEGG pathways, as these were considered most relevant to drug interaction. REVIGO [26] was used to visualize the GO molecular functions as a scatterplot by applying multidimensional scaling with GO terms pairwise semantic similarities.

2.3. Data-Mining for Drugs Interacting with Hub-Nodes. Gene-nodes in the PPI network with a degree ≥2 were considered as hub genes. Hub genes and proteins are considered highly relevant to biological functions [27]. Data for drugs interacting with the hub genes was sought from the ‘drug gene interaction database’ (DGIdb), and these drugs were labelled as candidate drugs affecting the risk of BRONJ.

3. Results

3.1. Dataset and Identification of DEGs. 751 annotated DEGs (log FC ≥1.5, p < 0.05) were obtained by analysis of the microarray gene expression dataset GSE7116 (Figure 1) including 148 upregulated and 603 downregulated DEGs. The top 10 upregulated and downregulated DEGs are listed in Table 1.

3.1.1. Protein-Protein Interaction (PPI) Network and Functional Enrichment Analysis. The PPI network included 633 nodes and 168 edges with an average node degree of 0.531 and an average local clustering coefficient of 0.111. The PPI enrichment p value was 9.99e-16, suggesting significant biological connectivity. The PPI network was then clustered into 3 modules using k-means clustering containing 193 nodes in the red module, 243 nodes in the green module and 197 in the green module (Figure 2). 49 nodes in the PPI network had a degree ≥2. TBP, AK6, and various TAF genes in the green module showed the highest connectivity in the PPI network, followed by various POLR genes in the red and blue modules.

Functional enrichment analysis of the STRING PPI network showed 52 overrepresented GO molecular functions...
3.2. Data-Mining for Drugs Interacting with Hub-Nodes. 37 drugs identified by data mining in the DGIdb database for 9 hub genes, TBP, TAF1, PPP2CA, PRPF31, CASP8, UQCRB, ACTR2, CFLAR, and FAS are listed in Table 3. All 9 genes were among downregulated genes. Anticancer chemotherapeutics were the most frequently represented. Targeted therapy agents including angiogenic kinase inhibitors and immunomodulators were also noted. Hormonal agonist and antagonist, Atrovastatin and Metformin were also among the noted drugs (Table 3).

4. Discussion

The present study identified multiple candidate drugs that may affect the risk for BRONJ in cancer using a bioinformatics approach. Genes that were deregulated in multiple myeloma patients presenting with BRONJ as compared to multiple myeloma patients on bisphosphonates without BRONJ were identified. Utilizing the genes with high interconnectivity in the PPI-network of the DEGs, interacting drugs were sought. 9 DEGs downregulated in BRONJ that were hub nodes in the PPI network were found to interact with 37 drugs and these were identified as candidate drugs.

A highly interconnected module of Tata binding protein- (TBP-) associated factors (TAF) genes was noted in the PPI network, and the topmost enriched KEGG pathway was basal transcription factors. TBP-associated factors (TAF) are implicated in the initiation of transcriptional switches [28] and considered as targets in cancer [29]. TBP-related pathways are considered to contribute to stress-related checkpoint and apoptosis pathways, and are targeted by anticancer drug Etoposide [30]. Etoposide is shown to inhibit bone formation with apoptosis of bone marrow cells [31] and implicated MRONJ in myeloma [25]. The TAF interacting chemotherapeutic Doxorubicin has also been associated with osteonecrosis [32, 33]. Similarly, the anthracycline agent Daunorubicin has also been associated with osteonecrosis in case reports [34]. Conventional cytotoxic chemotherapeutic agents including Cyclophosphamide, Etoposide, Cisplatin, and Anthracyclines are widely applied in cancer including multiple myeloma and are associated with several immune perturbations [35]. At the same time, antiresorptive agents are commonly prescribed in multiple myeloma. Cyclophosphamide has been reported to increase the risk of BRONJ among multiple myeloma patients receiving Pamlidronate therapy [36], and a dose-dependent effect has been observed in animal experiments [19]. The combination of Cyclophosphamide with zoledronic acid has been shown to upregulate IL-6 and reduce the expression of CCR-7, CXCL12, CXCRI4, and CD115 [37]. In agreement, in the present study, CXCRI chemokine receptor and CCR binding GO molecular functions and IL-17 KEGG pathway were enriched in BRONJ. BRONJ has also been documented following Cisplatin therapy upon initiation of bisphosphonate zoledronic acid [38].

Emricasan and Nivocasan are novel broad-spectrum, small molecule, caspase inhibitors that target apoptosis pathways in disease [39, 40]. Emricasan has been applied in the treatment of acute myeloid leukemia along with second.
mitochondria derived activator of caspases (SMAC) mimetics [39] and in liver disease [41]. The effect of novel caspase inhibitor molecules in MRONJ or BRONJ is not reported, but elevated NLRP3/caspase expression is reported to mediate BRONJ in diabetic patients [42]. Therefore, it may be hypothesized that caspase inhibition in conjunction with bisphosphonate agents may reduce the risk for BRONJ. In addition, caspase inhibition has been associated with alterations in osteogenic processed [43]. Recent data has shown that caspase inhibitors can act to limit alveolar bone resorption after tooth extraction [44]. These findings support a potential role of pan-caspase inhibitors in the prevention and management of BRONJ.

Targeted cancer therapies have enabled improved cancer outcomes with better adverse effect profiles [45]. Conatumumab is a proapoptotic death receptor 5 agonist antibody that has been trialled in multiple cancers [46, 47]. It acts by targeting TRAIL (tumor-necrosis factor related apoptosis-inducing ligand, CD253) R2, which is currently a focus on investigation [48]. Little is known about TRAIL-R agonistic antibodies and the risk of BRONJ. Notably, TRAIL agonists have shown good efficacy against osteosarcoma cell lines but show low to moderate treatment effects, so coadministration with sensitizing agents has been considered [49]. Bisphosphonates have been documented to increase the sensitivity of osteosarcoma cells to TRAIL agonists via death receptor 5 [50], but their role in copotentiating BRONJ is not clear.

Nintedanib and Dovitinib are antiangiogenic tyrosine kinase inhibitors [51]. BRONJ has been reported in patients receiving antiangiogenic tyrosine kinase inhibitors and concomitant bisphosphonate therapies, with 5.9 times increased incidence in combination therapy as compared to bisphosphonate alone [52, 53]. Ofanerogene Obadenovec, a targeted antiangiogenic gene therapy, has shown promising outcomes [54, 55] and is currently under investigation. Little is yet understood about its risk for BRONJ. The novel endoplasmic reticulum targeted phospholipid Edelfosine promotes apoptosis of tumor cells [56], but its risk for BRONJ is not documented. The isoflavene Idronoxil was found to enhance tumor cell apoptosis and CD8+ T cell function [57], but its role in BRONJ is not known. The novel CD95-Ligand inhibitor Asunercept can inhibit apoptosis of tumor infiltrating lymphocytes and is considered a promising adjunctive therapy for multiple cancers including gliomas and myelodysplastic syndromes [58] Earlier work has shown that FAS/CD95 is implicated in steroid mediated osteonecrosis [59]; supporting a hypothesis that CD95 blockade may reduce the risk for BRONJ.

Steroid hormones testosterone, progesterone, and androgen antagonists were among the candidate drugs linked to
Figure 3: Overrepresented GO molecular functions in the PPI network represented in a semantic space by multidimensional Scaling (MDS) using REVIGO. Semantically similar GO terms are projected together. The color scale represents log FDR values.

| GO molecular function | Description                        | Strength |
|-----------------------|------------------------------------|----------|
| GO: 0031730           | CCR5 chemokine receptor binding    | 1.25     |
| GO: 1990405           | Protein antigen binding            | 1.25     |
| GO: 0017162           | Aryl hydrocarbon receptor binding  | 1.14     |
| GO: 0016251           | RNA polymerase II general          | 0.99     |
| GO: 0045236           | CXCR chemokine receptor binding    | 0.93     |
| GO: 0003899           | DNA-directed 5-3 RNA polymerase    | 0.83     |
| GO: 0035035           | Histone acetyltransferase binding  | 0.81     |
| GO: 0042379           | Chemokine receptor binding         | 0.65     |
| GO: 0016779           | Nucleotidyltransferase activity    | 0.51     |
| GO: 0035257           | Nuclear hormone receptor binding   | 0.5      |

| KEGG pathway          | Description                                | Strength |
|-----------------------|--------------------------------------------|----------|
| hsa03022              | Basal transcription factors                | 1.020    |
| hsa03020              | RNA polymerase                            | 0.950    |
| hsa05140              | Leishmaniasis                             | 0.790    |
| hsa04064              | NF-kappa B signaling pathway               | 0.740    |
| hsa04657              | IL-17 signaling pathway                    | 0.700    |
| hsa05133              | Pertussis                                  | 0.700    |
| hsa05134              | Legionellosis                              | 0.700    |
| hsa04668              | TNF signaling pathway                      | 0.670    |
| hsa05323              | Rheumatoid arthritis                       | 0.670    |
| hsa05144              | Malaria                                    | 0.670    |

*FDR adjusted p value < 0.05.
BRONJ. Sex steroids are implicated in bone metabolism, and exogenous estrogen or androgens can increase the risk of osteonecrosis [60]. Androgen and androgen antagonists are highly relevant to prostate cancer management. CYP3A4 polymorphism has been associated with both Finasteride concentrations and osteonecrosis [61, 62]. Total androgen blockade with Bicalutamide has been associated with MRONJ [63]. Testosterone therapy has also been linked with osteonecrosis in conjunction with thrombophilia [64].

Metformin interacting with PRPF31 was documented in the present study. Diabetes is a known risk factor for BRONJ [17]. Animal data has demonstrated that metformin attenuated zoledronic acid mediated BRONJ [65]. Metformin has been found to upregulate osteoblast differentiation while inhibiting osteoclastic activity and can exert protective effects against ischemic osteonecrosis [66]. Statins are implicated in bone metabolism and statin therapy lowers risk of osteonecrosis in steroid therapy [67]. Preclinical data has shown single topical Fluvastatin therapy may aid in the healing of BRONJ lesions [68]. Lithium was found to activate B catenin and protect from steroid-mediated osteonecrosis [69], and lithium nanoparticles may be useful in BRONJ prevention and management [70]. Its role in mitigating BRONJ is not clear. The ginseng saponin 20(S)-protopanaxadiol-ginsegnsiside inhibits tumor growth by suppressing NF-kappa B signaling [71]. BAY 11-7085 is a suppressor of nuclear factor kappa beta signaling [72]. Bisphosphonates disrupt osteoclast activity via NF-kappa B signaling [73]. The NF-kappa B signaling KEGG pathway was enriched in BRONJ. The effect of novel NF-kappa B suppressors on BRONJ remains to be ascertained.

Overall, many of the identified agents were supported by experimental or clinical evidence. Molecular functions and signaling pathways enriched in BRONJ were also identified, and other drugs interacting with these may be considered as risk modulators for BRONJ. The findings of this exploratory bioinformatics study must be considered as preliminary data that provide hypothetical basis for specific drug-drug interactions.
interactions in the risk and pathogenesis of BRONJ/MRONJ. On the basis of these findings, clinical studies and in vitro experiments may be designed.

The major limitation of the present study is the inclusion of a single dataset pertaining to a small number of samples from multiple myeloma patients. The included dataset contained samples from patients on multiple bisphosphonate agents including pamidronate, zoledronic acid, or both [24], which are nitrogen containing bisphosphonates with the highest risk of BRONJ [74]. Therefore, the present analysis cannot discriminate the role of agent-specific drug-drug interactions in BRONJ or be extrapolated to nonnitrogen containing agents. As the risk of BRONJ is higher with the nitrogen-containing agents, nonnitrogen containing agents etidronate and clodronate have been applied as substitution drugs to reduce the risk of BRONJ, owing to their different molecular mechanisms of action [75]. The interactions of nonnitrogen containing bisphosphonates with other agents and the influence on BRONJ risk remain to be addressed. In addition, the candidate drugs were determined using a single database, and other knowledge discovery approaches such as molecular docking analysis were not utilized in the present study. Finally, the present study addressed intravenous bisphosphonates in malignancy, which imposes a higher risk of BRONJ as compared to oral bisphosphonates used for osteoporosis. Additionally, exome sequencing has shown evidence for genetic associations with BRONJ via modulation of posttranslational activity in osteoclasts [76], suggesting the need for pharmacogenomics investigations. Larger datasets, based on multiple cancers and other indications of bisphosphonate therapy, and deep phenotyping are essential to data mine all potential drugs relevant to MRONJ and acquire insights for clinical and experimental translation. In addition, the inclusion of RNA-seq and single cell genomics datasets and integration of multiomic and pharmacogenomic approaches can enable wider understanding of drugs influencing BRONJ.

5. Conclusion

Overall the present study identified several conventional and novel drugs including antineoplastic, antiangiogenic tyrosine kinase inhibitor, caspase inhibitor, steroid hormone, and hormonal antagonist drugs that may potentially increase risk of BRONJ in patients receiving concomitant bisphosphonate therapies. Metformin, statins, lithium, and the novel CD95-ligand inhibitor Asunercept were identified as potentially protective drugs against BRONJ. These findings provide preliminary basis for experimental research.

Data Availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

JZ conceptualized the research idea and study design, performed the bioinformatics analyses, wrote the manuscript, and administered and supervised the whole research project. JZ, CZ, YS, and PK reviewed and edited the manuscript. YJ administered and supervised the whole research project. All coauthors read and approved the whole manuscript.

References

[1] J.-J. Body, R. Bartl, P. Burckhardt et al., “Current use of bisphosphonates in oncology. International bone and cancer study group,” Journal of Clinical Oncology, vol. 16, no. 12, pp. 3890–3899, 1998.
[2] G. De Rosa, G. Misso, G. Salzano, and M. Caraglia, “Bisphosphonates and cancer: what opportunities from nanotechnology?,” Journal of drug delivery, vol. 2013, Article ID 637976, 17 pages, 2013.
[3] J.-P. Devogelaer, “Treatment of bone diseases with bisphosphonates, excluding osteoporosis,” Current Opinion in Rheumatology, vol. 12, no. 4, pp. 331–335, 2000.
[4] J.-V. Torregrosa and A. M. Ramos, “Use of bisphosphonates in chronic kidney disease,” Nefrologia (English Edition), vol. 30, no. 3, pp. 288–297, 2010.
[5] R. Landesberg, S. Eisig, I. Fennoy, and E. Siris, “Alternative indications for bisphosphonate therapy,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 5, pp. 27–34, 2009.
[6] J. Body and I. Mancini, “Bisphosphonates for cancer patients: why, how, and when?,” Supportive Care in Cancer, vol. 10, no. 5, pp. 399–407, 2002.
[7] M. T. Drake, B. L. Clarke, and S. Khosla, “Bisphosphonates: mechanism of action and role in clinical practice,” Mayo Clinic Proceedings, vol. 83, no. 9, pp. 1032–1045, 2008.
[8] I. Diel, S. Ansorge, D. Hohmann, C. Giannopoulou, D. Niepel, and M. Intorcia, Real-World Use of Denosumab and Bisphosphonates in Patients with Solid Tumours and Bone Metastases in Germany, vol. 28, no. 11, 2020.
[9] R. K. Hernandez, A. Adhia, S. W. Wade et al., “Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States,” Clinical Epidemiology, vol. 7, p. 335, 2015.
[10] T. Shibahara, T. Morikawa, K. Yago, H. Kishimoto, Y. Imai, and K. Kurita, “National survey on bisphosphonate-related osteonecrosis of the jaws in Japan,” Journal of Oral and Maxillofacial Surgery, vol. 76, no. 10, pp. 2105–2112, 2018.
[11] Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, “American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws,” American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonaterelated osteonecrosis of the jaws. J Oral Maxillofac Surg, vol. 65, no. 3, pp. 369–376, 2007.
[12] S. L. Ruggiero, “Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ),” Clinical Cases in Mineral and Bone Metabolism, vol. 4, no. 1, pp. 37–42, 2007.
[13] A. Barasch, J. Cunha-Cruz, F. A. Curro et al., “Risk factors for osteonecrosis of the jaws,” Journal of Dental Research, vol. 90, no. 4, pp. 439–444, 2011.
Disease Markers

[14] M. Kos, "Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates," *Archives of Medical Science. AMS*, vol. 11, no. 2, pp. 319–324, 2015.

[15] L. B. Nozari, V. N. Pacheco, A. L. Freddo, D. Ponzoni, and A. Corsetti, "Prevalence of bisphosphonate-related osteonecrosis of the jaws associated with dental extraction: systematic review," *J Dent Maxillofacial Res*, vol. 1, no. 2, pp. 72–77, 2018.

[16] L. A. Assael, "Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies," *Journal of Oral and Maxillofacial Surgery*, vol. 67, no. 5, pp. 35–43, 2009.

[17] T. Yoneda, H. Hagino, T. Sugimoto et al., "Bisphosphonate-related osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology, and Japanese society of oral and maxillofacial surgeons," *Journal of Bone and Mineral Metabolism*, vol. 28, no. 4, pp. 365–383, 2010.

[18] L. B. Silva, G. M. Sampaio, R. S. C. Cunha et al., "Bisphosphonates and their indication to prevent bone density loss in cancer therapy," *Research, Society and Development*, vol. 11, no. 4, p. e27611421577, 2022.

[19] A. Marciano, Y. Ingrasciotta, V. Isgrò et al., "Cancer patients at risk for medication-related osteonecrosis of the jaw. A case and control study analyzing predictors of MRONJ onset," *Journal of Clinical Medicine*, vol. 10, no. 20, p. 4762, 2021.

[20] S. Kuroshima, M. Sasaki, K. Nakajima, H. Hayano, and T. Sawase, "Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice," *Bone*, vol. 112, pp. 177–186, 2018.

[21] O. Nicolotou-Galitis, M. Kouri, E. Papadopoulou et al., "Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review," *Supportive Care in Cancer*, vol. 27, no. 2, pp. 383–394, 2019.

[22] K.-Y. Kim, X. Zhang, and I.-H. Cha, "Identifying a combined biomarker for bisphosphonate-related osteonecrosis of the jaw," *Clinical Implant Dentistry and Related Research*, vol. 20, no. 2, pp. 191–198, 2018.

[23] J. He, Q. Zhou, X. Jia, P. Zhou, and C. Lin, "Immune-related expression profiles of bisphosphonates-related osteonecrosis of the jaw in multiple myeloma," *Die Pharmazie-An Interna-tional Journal of Pharmaceutical Sciences*, vol. 76, no. 4, pp. 159–164, 2021.

[24] N. Raje, S. B. Woo, K. Hande et al., *Clinical, radiographic, and biomarker characterization of multiple myeloma patients with bisphosphonate associated osteonecrosis of the jaw*, pp. 3591–3591, 2006.

[25] D. Szkłarczyk, A. L. Gable, D. Lyon et al., "STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets," *Nucleic Acids Research*, vol. 47, no. D1, pp. D607–D613, 2019.

[26] F. Supek, M. Bošnjak, N. Škunca, and T. Šmuc, "REVIGO summarizes and visualizes long lists of gene ontology terms," *PLoS One*, vol. 6, no. 7, article e21800, 2011.

[27] P. Goymer, "Why do we need hubs?," *Nature Reviews Genetics*, vol. 9, no. 9, pp. 651–651, 2008.

[28] W. Akhtar and G. J. C. Veenstra, "TBP-related factors: a paradigm of diversity in transcription initiation," *Cell & Bioscience*, vol. 1, no. 1, pp. 12–23, 2011.

[29] J. R. Ribeiro, L. A. Lovasco, B. C. Vanderhyden, and R. N. Freeman, "Targeting TBP-associated factors in ovarian cancer," *Frontiers in Oncology*, vol. 4, p. 45, 2014.

[30] Y. Suenaga, T. Ozaki, Y. Tanaka et al., "TATA-binding protein (TBP)-like protein is engaged in etoposide-induced apoptosis through transcriptional activation of human TAp63 gene," *Journal of Biological Chemistry*, vol. 284, no. 51, pp. 35433–35440, 2009.

[31] A. J. Koh, B. P. Sinder, P. Entezami, L. Nilsson, and L. K. McCaulay, "The skeletal impact of the chemotherapeutic agent etoposide," *Osteoporosis International*, vol. 28, no. 8, pp. 2321–2333, 2017.

[32] K. Shim, M. J. MacKenzie, and E. Winquist, "Chemotherapy-associated osteonecrosis in cancer patients with solid tumours," *Drug Safety*, vol. 31, no. 5, pp. 359–371, 2008.

[33] S. Greuter, F. Schmid, T. Ruhstaller, and B. Thürilmann, "Bevacizumab-associated osteonecrosis of the jaw," *Annals of Oncology*, vol. 19, no. 12, pp. 2091-2092, 2008.

[34] P. Infante-Cossio, J.-C. Lopez-Martin, E. Gonzalez-Cardero, R. Martinez-de-Fuentes, and A. Casas-Fernandez-Tejerina, "Osteonecrosis of the maxilla associated with cancer chemotherapy in patients wearing dentures," *Journal of Oral and Maxillofacial Surgery*, vol. 70, no. 7, pp. 1587–1592, 2012.

[35] N. S. Raje, E. Anaissie, S. K. Kumar et al., "Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group," *The Lancet Haematology*, vol. 9, no. 2, pp. e143–e161, 2022.

[36] F. Jada, L. Lee, M. Pharaoh, D. Reece, and L. Wang, "A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients," *Annals of Oncology*, vol. 18, no. 12, pp. 2015–2019, 2007.

[37] S. Kuroshima, K. Nakajima, M. Sasaki et al., "Gene expression analysis of new extraction wounds prior to onset of bisphosphonate-related osteonecrosis of the jaw-like lesions in mice: a preliminary animal study," *Journal of Prosthodontic Research*, vol. 65, no. 4, pp. 546–553, 2021.

[38] A. A. Torres, B. L. de Freitas, P. P. Carneiro et al., "Medication-related osteonecrosis of the jaw and low-level laser therapy as adjuvant treatment: a case report," *Journal of Lasers in Medical Sciences*, vol. 11, no. 4, pp. 497–499, 2020.

[39] J. Kudelova, J. Fleischmannova, E. Adamova, and E. Matalova, "Pharmacological caspase inhibitors: research towards therapeuetic perspectives," *Journal of physiology and pharmacology: an official journal of the Polish Physiological Society*, vol. 66, no. 4, pp. 473–482, 2015.

[40] K. Li, M. F. van Delft, and G. Dewson, "Too much death can kill you: inhibiting intrinsic apoptosis to treat disease," *The EMBO Journal*, vol. 40, no. 14, article e107341, 2021.

[41] G. Garcia-Tsao, M. Fuchs, M. Schiffman et al., "Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension," *Hepatology*, vol. 69, no. 2, pp. 717–728, 2019.

[42] Q. Zhang, W. Yu, S. Lee, Q. Xu, A. Naji, and D. L. Anh, "Bisphosphonate induces osteonecrosis of the jaw in diabetic mice via NLRP3/Caspase-1-dependent IL-1β mechanism," *Journal
of Bone and Mineral Research, vol. 30, no. 12, pp. 2300–2312, 2015.

[43] E. Janečková, P. Bíliková, and E. Matalová, “Osteogenic potential of caspases related to endochondral ossification,” Journal of Histochemistry and Cytochemistry, vol. 66, no. 1, pp. 47–58, 2018.

[44] U. Y. Schwarz, F.-J. Strauss, and R. Gruber, “Caspase inhibitor attenuates the shape changes in the alveolar ridge following tooth extraction: a pilot study in rats,” Journal of Periodontal Research, vol. 56, no. 1, pp. 101–107, 2021.

[45] A. B. Troy, “Targeted cancer therapy: the next generation of cancer treatment,” Current Drug Discovery Technologies, vol. 12, no. 1, pp. 3–20, 2015.

[46] P. J. Kaplan-Lefko, J. D. Graves, S. J. Zoog et al., “Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types,” Cancer Biology & Therapy, vol. 9, no. 8, pp. 618–631, 2010.

[47] Y. Liu, H. Zhang, H. Cui et al., “Combined and targeted drugs delivery system for colorectal cancer treatment: conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers,” Drug Delivery, vol. 29, no. 1, pp. 342–350, 2022.

[48] V. J. Jr, A. Ozaiani, R. Lischke, J. Bartunkova, D. Smrz, and Z. Strizova, “The TRAIL in the treatment of human cancer: an update on clinical trials,” Frontiers in Molecular Biosciences, vol. 8, p. 628332, 2021.

[49] Z. Gamie, K. Kapriniotis, D. Papanikolaou et al., “TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: pre-clinical and clinical data,” Cancer Letters, vol. 409, pp. 66–80, 2017.

[50] M.-H. Moon, J.-K. Jeong, J.-S. Seo et al., “Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells _via_ death receptor 5 upregulation,” Experimental & Molecular Medicine, vol. 43, no. 3, pp. 138–145, 2011.

[51] M. J. Bueno, S. Mouron, and M. Quintela-Fandino, “Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach,” British Journal of Cancer, vol. 116, no. 9, pp. 1119–1125, 2017.

[52] L. Lorusso, L. Pieruzzi, M. Gabriele et al., “Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates,” Journal of Endocrinological Investigation, vol. 44, no. 12, pp. 2557–2566, 2021.

[53] T. van Cann, T. Loysen, A. Verbiest et al., “Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors,” Supportive Care in Cancer, vol. 26, no. 3, pp. 869–878, 2018.

[54] R. T. Penson, S. T. Berlin, A. M. Hanbury et al., Tumor responses and preliminary survival data in a phase II trial of ofranergene obadenovec (VB-111) combined with paclitaxel in patients with recurrent platinum resistant ovarian cancer, p. 5551, 2016.

[55] R. C. Arend, B. J. Monk, T. J. Herzog et al., “Utilizing an interim futility analysis of the OVAl study (VB-111/GOG 3018) for potential reduction of risk: a phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer,” Gynecologic Oncology, vol. 161, no. 2, pp. 496–501, 2021.

[56] F. Mollinedo and C. Gajate, “Direct endoplasmic reticulum targeting by the selective alkylphospholipid analog and antitumor ether lipid edelfosine as a therapeutic approach in pancreatic cancer,” Cancers, vol. 13, no. 16, p. 4173, 2021.

[57] N.-W. Kam, V. H.-F. Lee, T. Y. D. Hung et al., Effect of idronoxil combined with cisplatin on refractory immune responses in nasopharyngeal carcinoma, p. e15186, 2020.

[58] A. Krendyukov and C. Gieffers, “Asuncept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies,” Cancer Management and Research, vol. Volume 11, pp. 8095–8100, 2019.

[59] G. Kogiani, V. Mann, F. Ebetino et al., “Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis,” Life Sciences, vol. 75, no. 24, pp. 2879–2895, 2004.

[60] R. Kim, S. W. Kim, H. Kim, and S.-Y. Ku, “The impact of sex steroids on osteonecrosis of the jaw,” Osteoporosis and Sarcopenia, vol. 8, no. 2, pp. 58–67, 2022.

[61] C. H. Chau, D. K. Price, C. Till et al., “Finasteride concentrations and prostate cancer risk: results from the prostate cancer prevention trial,” PLoS One, vol. 10, no. 5, article e0126672, 2015.

[62] Y. Wang, X. Li, Y. Gao et al., “Genetic polymorphisms of CYP3A4 among Chinese patients with steroid-induced osteonecrosis of the femoral head,” Medicine, vol. 95, no. 44, p. e5332, 2016.

[63] L. Teoh, G. Moses, A. P. Nguyen, and M. J. McCullough, “Medication-related osteonecrosis of the jaw: analysing the range of implicated drugs from the Australian database of adverse event notifications,” British Journal of Clinical Pharmacology, vol. 87, no. 7, pp. 2767–2776, 2021.

[64] R. S. Pandit and C. J. Glueck, “Testosterone, anastrozole, factor V Leiden heterozygosity and osteonecrosis of the jaws,” Blood Coagulation & Fibrinolysis, vol. 25, no. 3, pp. 286–288, 2014.

[65] T. Nakagawa, S. Tsuka, F. Aonuma et al., “Effects of metformin on the prevention of bisphosphonate-related osteonecrosis of the jaw-like lesions in rats,” Journal of Prosthodontic Research, vol. 65, no. 2, pp. 219–224, 2021.

[66] S.-H. Park, M.-A. Kang, Y. J. Moon, K. Y. Jang, and J. R. Kim, “Metformin coordinates osteoblast/osteoclast differentiation associated with ischemic osteonecrosis,” Aging (Albany NY), vol. 12, no. 6, pp. 4727–4741, 2020.

[67] J. W. Pritchett, “Statin therapy decreases the risk of osteonecrosis in patients receiving steroids,” Clinical Orthopaedics and Related Research, vol. 386, no. 386, pp. 173–178, 2001.

[68] K. Sanda, Y. Ayukawa, N. Yasunami et al., “Therapeutic effect of fluvastatin on medication-related osteonecrosis of the jaw,” Journal of Periodontology, vol. 93, no. 6, pp. 837–846, 2022.

[69] Z. Yu, L. Fan, J. Li, Z. Ge, X. Dang, and K. Wang, “Lithium prevents rat steroid-related osteonecrosis of the femoral head by β-catenin activation,” Endocrine, vol. 52, no. 2, pp. 380–390, 2016.

[70] D. Li, X. Xie, Z. Yang, C. Wang, Z. Wei, and P. Kang, “Enhanced bone defect repairing effects in glucocorticoid-induced osteonecrosis of the femoral head using a porous nano-lithium-hydroxyapatite/gelatin microsphere/erythroptoin composite scaffold,” Biomaterials Science, vol. 6, no. 3, pp. 519–537, 2018.

[71] J.-L. Gao, G.-Y. Lv, B.-C. He et al., “Ginseng saponin metabolite 20 (S)-protopanaxadiol inhibits tumor growth by targeting multiple cancer signaling pathways,” Oncology Reports, vol. 30, no. 1, pp. 292–298, 2013.
[72] S. Mabuchi, M. Ohmichi, Y. Nishio et al., “Inhibition of NFκB Increases the Efficacy of Cisplatin in _in Vitro_ and _in Vivo_ Ovarian Cancer Models,” *Journal of Biological Chemistry*, vol. 279, no. 22, pp. 23477–23485, 2004.

[73] W. Zhang, L. Gao, W. Ren et al., “The role of the immune response in the development of medication-related osteonecrosis of the jaw,” *Frontiers in Immunology*, vol. 12, p. 606043, 2021.

[74] M. A. Dimopoulos, E. Kastritis, A. Anagnostopoulos et al., “Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid,” *Haematologica*, vol. 91, no. 7, pp. 968–971, 2006.

[75] T. Oizumi, K. Yamaguchi, K. Sato et al., “A strategy against the osteonecrosis of the jaw associated with nitrogen-containing bisphosphonates (N-BPs): attempts to replace N-BPs with the non-N-BP etidronate,” *Biological and Pharmaceutical Bulletin*, vol. 39, no. 9, pp. 1549–1554, 2016.

[76] J.-H. Kim, Y. J. Ko, J.-y. Kim et al., “Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics,” *PLoS One*, vol. 10, no. 2, p. e0118084, 2015.